First author of the article - Riten Kumar/LinkedIn
Jan 10, 2026, 14:40
Last day at ASH25 from Riten Kumar
Riten Kumar, Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
”Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda Boyala Kuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
All from ASH25 featured in Hemostasis Today.
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting
-
Jun 1, 2026, 13:23Skye Collado: Miller-Keystone Blood Center Expands Community Impact Through the Addition of New Bloodmobiles
-
Jun 1, 2026, 12:37Rutuja Mahadik: Anemia is More Than Just Feeling Tired
-
Jun 1, 2026, 12:36Ankur Jindal: Large-Vessel Inflammation and Immune Dysregulation in Wiskott–Aldrich Syndrome
-
Jun 1, 2026, 12:35Shadi Almassri: Conditions That Can Cause False High or False Low HbA1c Results
-
Jun 1, 2026, 12:22Ed Davidson: Clot Removing Technology That Can Change the Game
-
Jun 1, 2026, 12:17Tagreed Alkaltham: Building Blood Systems for Both Efficiency and Resilience
-
Jun 1, 2026, 11:16Ocima Richard Draza: Postpartum Hemorrhage – A Practical Step-by-Step Management Guide